[breadcrumb_custom]

Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) Is Now 9.4% Above Its 52-Week Low. How Long Will It Continue To Rise?

In last trading session, Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) saw 1.89 million shares changing hands with its beta currently measuring 1.92. Company’s recent per share price level of $5.32 trading at $0.02 or 0.38% at ring of the bell on the day assigns it a market valuation of $1.09B. That closing price of BCRX’s stock is at a discount of -101.88% from its 52-week high price of $10.74 and is indicating a premium of 9.4% from its 52-week low price of $4.82. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.32 million shares which gives us an average trading volume of 3.87 million if we extend that period to 3-months.

Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) trade information

Upright in the green during last session for gaining 0.38%, in the last five days BCRX remained trading in the green while hitting it’s week-highest on Wednesday, 02/07/24 when the stock touched $5.32 price level, adding 3.97% to its value on the day. Biocryst Pharmaceuticals Inc.’s shares saw a change of -11.19% in year-to-date performance and have moved 0.76% in past 5-day. Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) showed a performance of -28.49% in past 30-days. Number of shares sold short was 28.05 million shares which calculate 5.85 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Biocryst Pharmaceuticals Inc. (BCRX) estimates and forecasts

Statistics highlight that Biocryst Pharmaceuticals Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -23.89% of value to its shares in past 6 months, showing an annual growth rate of 18.80% while that of industry is 11.30. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 36.80% in the current quarter and calculating 21.40% increase in the next quarter. This year revenue growth is estimated to rise 21.00% from the last financial year’s standing.

10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $90.01 million for the same. And 6 analysts are in estimates of company making revenue of $87.65 million in the next quarter that will end on Mar 2024. Company posted $79.55 million and $68.78 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 13.20% while estimating it to be 27.40% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -11.25% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 21.00% while estimates for its earnings growth in next 5 years are of 44.80%.

BCRX Dividends

Biocryst Pharmaceuticals Inc. is more likely to be releasing its next quarterly report between February 19 and February 23 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

On Key

Related Posts